Shao YH, Albertsen PC, Roberts CB, et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/mL. Arch Intern Med 2010 July
26;170(14):1256-1261.
RO-7.1 External Beam Therapy
Buyyounouski MK, Price RA Jr, Harris EE, et al. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010
Apr;76(5):1297-1304.
Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):361-368.
Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of slvage radiation therapy for recurrent prostate cancer after definitive prostatectomy. J Clin Oncol 2007 May 20;25(15):2035-2041. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs
observation in men with biochemical recurrence after definitive prostatectomy. JAMA
2008;299(23):2760-2769.
Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a
randomized clinical trial. J Urol 2009 March;181(3):956-962.
Bernard JR Jr, Buskirk SJ, Heckman MG, et al. Salvage radiotherapy for rising prostate-specific antigen levels after definitive prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 2010 March 1:76(3):735-740.
Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005 Nov
10;23(32):8146-8151.
American Urological Association Prostate Cancer: guideline for the management of clinically localized prostate cancer: 2007 update. http://www.auanet.org/content/ guidelines-and-quality-care/clinical- guidelines/main-reports/proscan07/content.pdf. Accessed February 2, 2011.
RO-7.2 Brachytherapy
Merrick GS, Zelefsky MJ, Sylvester J, et al. American Brachytherapy Society Prostate Low-Dose Rate Task Group. Not dated. http://www.americanbrachytherapy.org/guidelines/prostate_low-
doseratetaskgroup.pdf. Accessed February 2, 2011.
Hsu IC, Yamada Y, Vigneault E, et al. American Brachytherapy Society Prostate High-Dose Rate Task Group. August 2008, http://www.americanbrachytherapy.org/guidelines/HDRTaskGroup.pdf. Accessed
February 2, 2011.
Taira AV, Merrick GS, Galbreath RW, et al. Natural history of clinically staged low- and intermediate- risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010 Feb 1;76(2):349-354.
Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010 Jun 2 (e-pub ahead
of print). doi: 10.1016/j.ijrobp.2010.01.005.
RO-10~HEAD and NECK CANCER
Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol
2010; 11:85-91.
Clark CH et al. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid- sparing IMRT for locally advanced head and neck cancer. Br J Radiol 2009; 82: 585-94.
Pfister DG et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Head and neck cancers. J Natl Compr Canc Netw 2011; 9: 596-650.
Bhide SA, Nutting CM. Advances in radiotherapy for head and neck cancer. Oral Oncol 2010; 46: 439-
41.
Bourhis J et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open- label phase 3 randomised trial. Lancet Oncol 2012; 13: 145-53.
Chan AT, Gregoire V, Lefebvre JL, Licitra L, Felip E. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v187-9.:
v187-v189.
Chen L et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent
chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012; 13: 163-71.
Chen QY et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 2011; 103: 1761-70.
Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007; 85: 156-70.
Daly-Schveitzer N, Julieron M, Tao YG, Moussier A, Bourhis J. Intensity-modulated radiation therapy (IMRT): toward a new standard for radiation therapy of head and neck cancer? Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128: 241-7.
Erickson BA et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2011; 79: 641-9.
Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS- ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21
Suppl 5:v184-6.: v184-v186.
Hall SF, Groome PA, Irish J, O'Sullivan B. Radiotherapy or surgery for head and neck squamous cell cancer: establishing the baseline for hypopharyngeal carcinoma? Cancer 2009; 115: 5711-22.
Mallick I, Waldron JN. Radiation therapy for head and neck cancers. Semin Oncol Nurs 2009; 25: 193-
202.
Mazeron JJ et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009; 91: 150-6.
McDonald MW et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1292-8.
Mesia NR, Pastor BM, Cruz Hernandez JJ, Isla CD. SEOM clinical guidelines for the treatment of head and neck cancer. Clin Transl Oncol 2010; 12: 742-8.
NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers (www.NCCN.org) - Version 1.2012. NCCN.org 4-26-2012.
Nutting CM et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-36. Salama JK et al. ACR appropriateness criteria(R) adjuvant therapy for resected squamous cell carcinoma
of the head and neck. Oral Oncol 2011; 47: 554-9.
Shibuya H. Current status and perspectives of brachytherapy for head and neck cancer. Int J Clin Oncol
2009; 14: 2-6.
Thariat J et al. New techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions. Improved effectiveness and safety? Impact on survival? Anticancer Drugs
2011; 22: 596-606.
Zackrisson B et al. Two-year results from a Swedish study on conventional versus accelerated
radiotherapy in head and neck squamous cell carcinoma--the ARTSCAN study. Radiother Oncol 2011;
100: 41-8.
RO-11~GYNECOLOGICAL CANCER